Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1195485 | 1.00 | HTT (0.44) | HTTSMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL5872024 | 0.87 | HTT (0.44) | HTTSMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL1194647 | 0.87 | ALDH1A1 (0.52) | HTTSMN1; SMN2MAPTALDH1A1ATM | |
| SCHEMBL1193123 | 0.87 | MEN1 (0.55) | HTTSMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL1195127 | 0.87 | ALDH1A1 (0.53) | HTTSMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL1193124 | 0.87 | MEN1 (0.55) | HTTSMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL1194643 | 0.87 | ALDH1A1 (0.52) | HTTSMN1; SMN2MAPTALDH1A1ATM | |
| SCHEMBL1195126 | 0.87 | ALDH1A1 (0.53) | HTTSMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL5872020 | 0.87 | HTT (0.44) | HTTSMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL1194908 | 0.84 | ALDH1A1 (0.57) | SMN1; SMN2MAPTALDH1A1LMNAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150238448-A1 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS, INC (US) | 2015-08-27 | — | — | US | disclosed |
| EP-2769719-A1 | Formulations of radioprotective alpha, beta unsaturated aryl sulfones | Onconova Therapeutics, Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2046343-B1 | FORMULATIONS OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS INC (US) | 2014-05-14 | — | — | EP | disclosed |
| EP-1909775-B1 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS INC (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110028504-A1 | Formulation of radioprotective alpha beta unsaturated aryl sulfones | ONCONOVA THERAPEUTICS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| EP-1223923-B1 | UNSATURATED ARYL SULFONES FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | UNIV TEMPLE (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090247624-A1 | FORMULATIONS OF RADIOPROTECTIVE ALPHA BETA UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-7595347-B2 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | Temple University—Of the Commonwealth System of Higher Education (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1370253-B1 | USE OF ALPHA, BETA UNSATURATED ARYL SULFONES FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY | UNIV TEMPLE (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7056953-B2 | (E)-styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1173160-B1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2005-06-22 | — | — | EP | disclosed |
| US-6787667-B2 | POLYSULFONSTYRENE POLYMER | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-09-07 | — | — | US | disclosed |
| US-6767926-B1 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-07-27 | — | — | US | disclosed |
| US-6762207-B1 | TARGETING RECEPTOR TYROSINE KINASES; SELECTIVE TUMOR CELL APOPTOSIS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-07-13 | — | — | US | disclosed |
| US-6667346-B2 | Administration of a radioprotective alpha, beta unsaturated aryl sulfone compound to a patient prior to anticancer radiotherapy reduces cytotoxic side effects of radiation on normal cells | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-12-23 | — | — | US | disclosed |
| US-6656973-B2 | Anticancer chemotherapy, and cytoprotective agents administered before, during or after chemotherapy to protect the normal cells of the patient | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247624-A1 | FORMULATIONS OF RADIOPROTECTIVE ALPHA BETA UNSATURATED ARYL SULFONES | ARSA, DEGS1, AHR | HTT 2780/4885SMN1; SMN2 810/4885MAPT 3406/4885 |
| US-20150238448-A1 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ARSA, AHR, SULT2A1 | HTT 2987/4885SMN1; SMN2 1138/4885MAPT 3381/4885 |
| US-20110028504-A1 | Formulation of radioprotective alpha beta unsaturated aryl sulfones | DEGS1, ARSA, ABCE1 | HTT 2485/4885SMN1; SMN2 1234/4885MAPT 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.